BioSpace - Medivation, Inc. News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Medivation, Inc.

201 Spear Street
3rd Floor
San Francisco California 94105 U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

Key Statistics

Email: info@medivation.com
Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN

Industry
Biopharmaceutical

Collaborations
Pfizer Inc.

Company News

Medivation, Inc. (MDVN) Names Stephen Kelsey Senior Vice President of New Projects 5/14/2013 10:22:06 AM More...

Medivation, Inc. (MDVN) Reports First Quarter Financial Results and Provides Corporate Update 5/10/2013 10:42:21 AM More...

Medivation, Inc. (MDVN) Announces Participation at Upcoming Investor Conferences 5/7/2013 10:17:45 AM More...

Medivation, Inc. (MDVN) Elects Wendy L. Yarno to Board of Directors 4/30/2013 11:25:57 AM More...

Astellas Pharma Inc. (YPH.BE), Medivation, Inc. (MDVN) Release: Positive CHMP Opinion for Xtandi ™ (Enzalutamide) in Advanced Prostate Cancer 4/26/2013 10:07:22 AM More...

Medivation, Inc. (MDVN) Announces First Quarter 2013 Financial Results Teleconference on May 9, 2013 4/25/2013 12:16:40 PM More...

Medivation, Inc. (MDVN) Elects Dawn Graham to Board of Directors 4/23/2013 11:35:23 AM More...

Medivation, Inc. (MDVN) and Astellas Pharma Inc. (YPH.BE) Provide Update on PREVAIL 4/1/2013 6:36:58 AM More...

Medivation, Inc. (MDVN) Announces Participation at Upcoming Investor Conference 3/7/2013 9:43:23 AM More...

Medivation, Inc. (MDVN) Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Corporate Update 3/1/2013 9:22:28 AM More...

1